tbuckley/cabot-search huggingface dataset:
A phase 1 study of niraparib in Japanese patients with advanced solid tumors
Authors: Ryota Shibaki, Toshio Shimizu, Shunsuke Kondo, Satoru Iwasa, Takafumi Koyama, Shigehisa Kitano, Jun Sato, Akihiko Shimomura, Ajit Suri, Yoichi Kase, Shuuji Sumino, Kenji Tamura, Noboru Yamamoto, Kan Yonemori
Journal: Annals of Oncology (2019)
Spliceosome GENE MUTATIONS ARE Also PRESENT In the Diverse Mutational Spectrum of CHRONIC Myelomonocytic LEUKEMIA
Authors: Hideki Makishima, Anna M Jankowska, Valeria Visconte, Ramon V. Tiu, Kathryn M Guinta, Hadrian Szpurka, Yuka Sugimoto, Christine L. O'Keefe, Alan F. List, Mikkael A Sekeres, Michael A McDevitt, Jaroslaw P. Maciejewski
Journal: Blood (2011)
A guide to prospective meta-analysis
Authors: Anna Lene Seidler, Kylie E Hunter, Saskia Cheyne, Davina Ghersi, Jesse A Berlin, Lisa Askie
Journal: BMJ (2019)

In a prospective meta-analysis (PMA), study selection criteria, hypotheses, and analyses are specified before the results of the studies related to the PMA research question are known, reducing many of the problems associated with a traditional (retrospective) meta-analysis. PMAs have many advantages: they can help reduce research waste and bias, and they are adaptive, efficient, and collaborative. Despite an increase in the number of health research articles labelled as PMAs, the methodology remains rare, novel, and often misunderstood. This paper provides detailed guidance on how to address the key elements for conducting a high quality PMA with a case study to illustrate each step.
Exposure-Response Analysis to Assist Selection of Dose and Treatment Duration for Polatuzumab Vedotin As a Single Agent or in Combination with Rituximab for the Treatment of B-Cell Lymphoma
Authors: Dan Lu, Jin Yan Jin, Leonid Gibiansky, William R. Gillespie, Priya Agarwal, Cheryl Jones, Yu-Waye Chu, Michael K. Wenger, Jamie Hirata, Chunze Li, Sandhya Girish
Journal: Blood (2015)
Simultaneous and sequential treatment of cancer with tuberculosis: Experience from a tuberculosis control unit in Japan
Authors: Yoshitaka Seki, Taisuke Kazuyori, Shota Fujimoto, Akihito Sato, Masami Yamada, Yumie Yamanaka, Kyuto Odashima, Ikumi Fujisaki, Aya Seki, Takeo Ishikawa, Naoko Morita, Kazuyoshi Kuwano
Journal: Annals of Oncology (2019)
A Phase I Study of Vorinostat, Lenalidomide, and Dexamethasone In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Excellent Tolerability and Promising Activity In a Heavily Pretreated Population
Authors: Paul Richardson, Donna Weber, Constantine S. Mitsiades, Meletios A. Dimopoulos, Jean-Luc Harousseau, Jennifer Houp, Thorsten Graef, Christine K Gause, Catriona Byrne, Kenneth C. Anderson, David Siegel
Journal: Blood (2010)
Imatinib Mesylate (STI571) Abrogates the Resistance to Doxorubicin in K562 Chronic Myeloid Leukemia Cells by Inhibition of BCR/ABL Kinase-Mediated DNA Repair.
Authors: Ireneusz Majsterek, Janusz Blasiak, Artur Slupianek, Tomasz Skorski
Journal: Blood (2005)
Smif (Smad4 Interacting Factor) Is a Negative Regulator of T Cell Activation and Autoimmunity In Vivo.
Authors: Wibke Leibig, Sebastian Kuhn, Thomas Patzelt, Claudia Mugler, Bai Ren-Yuan, Leticia Quintanilla-Fend, Irmgard Förster, Christian Peschel, Jürgen Ruland, Justus Duyster
Journal: Blood (2009)
Tregs Suppress GvHD at the Periphery and Unleash the Gvl Effect in the Bone Marrow
Authors: Loredana Ruggeri, Mauro Di Ianni, Elena Urbani, Antonella Mancusi, Franca Falzetti, Alessandra Carotti, Adelmo Terenzi, Maria Speranza Massei, Lucia Amico, Tiziana Zei, Roberta Iacucci, Massimo Fabrizio Martelli, Andrea Velardi
Journal: Blood (2014)
Autologous Stem Cell Transplantation in Waldenstrom's Macroglobulinemia
Authors: Krina Patel, Rima M Saliba, Nina Shah, Qaiser Bashir, Sheeba K. Thomas, Yvonne T Dinh, Chitra M. Hosing, Uday R. Popat, Simrit Parmar, Sergio A Giralt, Richard E. Champlin, Muzaffar H. Qazilbash
Journal: Blood (2012)
Increased DNA Damage and Error-Prone Repair in MPD/MDS Mice with Disease Progression: Key Indicators for Increased Genomic Instability.
Authors: Feyruz V. Rassool, Terry J. Gaymes, Nicola Brady, Nicholas Lea, Marika Pla, Thi Hai Phan, Scott Kogan, Christine Chomienne, Nicholas S. Thomas, Ghulam J. Mafti, Rose Ann Padua
Journal: Blood (2004)
Regulation of the Function of αvβ3 in Platelets by a Designed Peptide Targeting the αv Transmembrane Domain.
Authors: Hang Yin, Joanna S. Slusky, Bryan W. Berger, Rustem I. Litvinov, Gaston Vilaire, James D. Lear, William F. DeGrado, Joel S. Bennett
Journal: Blood (2006)
Grade III meningioma: 10 year single centre case series
Authors: Hari Mcgrath, Jose Lavrador, Ioannis Christodoulides, Prajwal Ghimire, Richard Gullan, Ranjeev Bhangoo, Keyoumars Ashkan, Francesco Vergani
Journal: Neuro-Oncology (2019)

Abstract Rationale WHO Grade 3 meningiomas are a rare, malignant subtype of meningioma. Few controlled case series detailing its treatment and follow-up are to be found in the literature. Methods Retrospective cohort study of patients treated in a single neuro-oncology centre in the period between September 2008 and March 2019 with an initial diagnosis of WHO Grade 3 meningioma. Demographic and clinical data has been collected from the available medical records. Results 9 patients were included in this series: 2 had convexity, 2 sphenoid wing, 2 parafalcine, 1 parasagittal with a further 3 multiple locations and 1 patient with parietal convexity meningioma. 3 tumours displayed rhabdoid features, whilst 4 displayed papillary features and a further 2 displayed epithelial structures. All patients underwent surgical intervention: 5 patients had a subtotal resection with 3 having total resection. 3/4 of reported Simpson Grading was grade 2, whilst the remaining 1/4 was grade 1. The extent of resection for 1 patient was uncertain. Post surgically, 6 received adjuvant radiotherapy, 2 had no further treatment and 1 received gamma knife therapy. No patient received chemotherapy. 5 patients saw no tumour recurrence at follow up appointments (mean 50 months). Within 2 years of their respective surgical interventions, 4 patients died due to tumour recurrence and associated complications (3 patients). Conclusion To establish a uniform approach to treatment of patients with WHO Grade 3 meningiomas is challenging. Management involves a patient-centred approach based on multidisciplinary meeting decisions. Multicentre registries may allow further conclusions.
Palbociclib (PAL) + cetuximab (CET) vs CET in patients (pts) with head and neck cancer: Asian subgroup analysis
Authors: Makoto Tahara, Jin Ching Lin, Assuntina Sacco, Jessica Ley, Peter Oppelt, Qi Shen, Kenneth Kern, Holger Thurm, Shaw Ling Wang, Jean Francois Martini, Justin Hoffman, Bohuslav Melichar, Douglas Adkins
Journal: Annals of Oncology (2019)
Prolonged Survival in Secondary CNS Lymphoma Following High Dose Thiotepa/Busulfan-Based Chemotherapy (HDTB) and Autologous Stem Cell Transplantation (ASCT): Single Institution Results From Calgary, Canada
Authors: Lesley E. Street, Nizar J. Bahlis, Karen Valentine, Deirdre A. Jenkins, Carolyn J Owen, Mona Shafey, Peter Duggan, Douglas A. Stewart
Journal: Blood (2012)
Feasibility and Efficacy of ABVD In Elderly Hodgkin Lymphoma Patients: Analysis of Two Randomized Prospective Multicenter Trials of the German Hodgkin Study Group (HD10 and HD11)
Authors: Boris Böll, Helen Görgen, Michael Fuchs, Bastian von Tresckow, Andreas Engert, Peter Borchmann
Journal: Blood (2010)
MDR1 Gene Expression Predicts Response and Progression-Free Survival Of Ph+ CML Patients On Second-Line Nilotinib Therapy After Imatinib Failure - 4-Year Follow-Up
Authors: Mridul Agrawal, Benjamin Hanfstein, Philipp Erben, Dominik Wolf, Thomas Ernst, Susanne Saussele, Alice Fabarius, Das Purkayasatha, Richard C. Woodman, Rüdiger Hehlmann, Wolf-Karsten Hofmann, Andreas Hochhaus, Martin C. Müller
Journal: Blood (2013)
Determinants of Intima-Media Thickness in the Young
Authors: Scott T. Chiesa, Marietta Charakida, Georgios Georgiopoulos, Frida Dangardt, Kaitlin H. Wade, Alicja Rapala, Devina J. Bhowruth, Helen C. Nguyen, Vivek Muthurangu, Rukshana Shroff, George Davey Smith, Debbie A. Lawlor, Naveed Sattar, Nicholas J. Timpson, Alun D. Hughes, John E. Deanfield
Journal: JACC. Cardiovascular imaging (2019)

This study characterized the determinants of carotid intima-media thickness (cIMT) in a large (n > 4,000) longitudinal cohort of healthy young people age 9 to 21 years.Greater cIMT is commonly used in the young as a marker of subclinical atherosclerosis, but its evolution at this age is still poorly understood.Associations between cardiovascular risk factors and cIMT were investigated in both longitudinal (ages 9 to 17 years) and cross-sectional (ages 17 and 21 years) analyses, with the latter also related to other measures of carotid structure and stress. Additional use of ultra-high frequency ultrasound in the radial artery at age 21 years allowed investigation of the distinct layers (i.e., intima or media) that may underlie observed differences.Fat-free mass (FFM) and systolic blood pressure were the only modifiable risk factors positively associated with cIMT (e.g., mean difference in cIMT per 1-SD increase in FFM at age 17: 0.007 mm: 95% confidence interval [CI]: 0.004 to 0.010; p < 0.001), whereas fat mass was negatively associated with cIMT (difference: -0.0032; 95% CI: 0.004 to -0.001; p = 0.001). Similar results were obtained when investigating cumulative exposure to these factors throughout adolescence. An increase in cIMT maintained circumferential wall stress in the face of increased mean arterial pressure when increases in body mass were attributable to increased FFM, but not fat mass. Risk factor-associated differences in the radial artery occurred in the media alone, and there was little evidence of a relationship between intimal thickness and any risk factor.Subtle changes in cIMT in the young may predominantly involve the media and represent physiological adaptations as opposed to subclinical atherosclerosis. Other vascular measures may be more appropriate for the identification of arterial disease before adulthood.
Fatigue in Chronic Myelogenous Leukemia Patients (pts) Treated with Tyrosine Kinase Inhibitors (TKI),
Authors: Aziz Nazha, Loretta A Williams, Hagop M. Kantarjian, Patricia S Ault, Araceli Garcia-Gonzalez, Janet L Williams, Alexandra Probst, Susan O'Brien, Elias Jabbour, Alfonso Quintas-Cardama, Quiling Shi, Charles S Cleeland, Jorge E. Cortes
Journal: Blood (2011)
Expression of Roundabout Receptor 4 (Robo-4) Confers a Negative Prognosis On Patients with Acute Myeloid Leukemia
Authors: Jasmin Wellbrock, Eik Vettorazzi, Gabi Vohwinkel, Thoren Müller, Marianne Klokow, Carsten Bokemeyer, Ulrike Bacher, Jürgen Krauter, Walter Fiedler
Journal: Blood (2012)
Intensifying Methotrexate (MTX) Dosage Reduces Treatment Failure in Adults with Burkitt or Burkitt-Like Leukaemia/Lymphoma (BL) Treated with an Adapted BFM Protocol.
Authors: Sudhir Tauro, Gulnaz Begum, Grete Fossum Lauritzsen, Jan Delabie, Claudia Roberts, Premini Mahendra, Harald Holte
Journal: Blood (2006)
Azacitidine (Vidaza®, Aza) and Donor Lymphocyte Infusions (DLI) In Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): Interim-Analysis From the AZARELA-Trial (NCT-00795548).
Authors: Thomas Schroeder, Akos Gabor Czibere, Nicolaus Kröger, Uwe Platzbecker, Gesine Bug, Kathrin Rieger, Thomas Luft, Ingmar Bruns, Fabian Zohren, Christine Wolschke, Roland Fenk, Rainer Haas, Guido Kobbe
Journal: Blood (2010)
In Silico and Functional Characterization of TBL1XR1 as a Tumor Suppressor in Large B-Cell Lymphomas
Authors: Bjoern Chapuy, Atanas Kamburov, Caroline A Coughlin, Chip Stewart, Andrew Dunford, Miyuki Aono, Jens Loeber, Christopher Sauer, Arthur Su, Margaretha G M Roemer, Scott J Rodig, Gad Getz, Margaret A. Shipp
Journal: Blood (2016)
Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial
Authors: Dietrich Wilhelm Beelen, Rudolf Trenschel, Matthias Stelljes, Christoph Groth, Tamás Masszi, Péter Reményi, Eva-Maria Wagner-Drouet, Beate Hauptrock, Peter Dreger, Thomas Luft, Wolfgang Bethge, Wichard Vogel, Fabio Ciceri, Jacopo Peccatori, Friedrich Stölzel, Johannes Schetelig, Christian Junghanß, Christina Grosse-Thie, Mauricette Michallet, Hélène Labussiere-Wallet, Kerstin Schaefer-Eckart, Sabine Dressler, Goetz Ulrich Grigoleit, Stephan Mielke, Christof Scheid, Udo Holtick, Francesca Patriarca, Marta Medeot, Alessandro Rambaldi, Maria Caterina Micò, Dietger Niederwieser, Georg-Nikolaus Franke, Inken Hilgendorf, Nils Rudolf Winkelmann, Domenico Russo, Gérard Socié, Régis Peffault de Latour, Ernst Holler, Daniel Wolff, Bertram Glass, Jochen Casper, Gerald Wulf, Helge Menzel, Nadezda Basara, Maria Bieniaszewska, Gernot Stuhler, Mareike Verbeek, Sandra Grass, Anna Paola Iori, Juergen Finke, Fabio Benedetti, Uwe Pichlmeier, Claudia Hemmelmann, Michael Tribanek, Anja Klein, Heidrun Anke Mylius, Joachim Baumgart, Monika Dzierzak-Mietla, Miroslaw Markiewicz
Journal: The Lancet Haematology (2019)
R-CHOP with or without Radiotherapy in Non-Bulky Limited-Stage Diffuse Large B Cell Lymphoma (DLBCL): Preliminary Results of the Prospective Randomized Phase III 02-03 Trial from the Lysa/Goelams Group
Authors: Thierry Lamy, Gandhi Damaj, Emmanuel Gyan, Pierre Soubeyran, Krimo Bouabdallah, Guillaume Cartron, Remy Gressin, Jérôme Cornillon, Anne Banos, Marie-Pierre Moles, Katell Le Dû, Mohamed Benchalal, Valerie Costes, Marie-Christine Bene, Vincent Delwail
Journal: Blood (2014)
The Humanized Anti-CD40 Antibody, SGN-40, Promotes Apoptosis Signaling and Is Effective in Combination with Standard Therapies in Lymphoma Xenograft Models.
Authors: Timothy S. Lewis, May S.K. Sutherland, Mechthild Jonas, Charles G. Cerveny, Renee McCormick, Alan F. Wahl, Jonathan G. Drachman, Iqbal S. Grewal, Che-Leung Law
Journal: Blood (2006)
F-627, a G-CSF Dimer, Stimulated a More Rapid Neutrophil Recovery In Cyclophosphamide-Treated Monkeys Compared to Monomer Rhg-CSFs.
Authors: Zheng Tao Hu, Zhi Hua Huang, Xiao Bo Cen, Tao Wang, Kun Zhuang, Hong Zhou Yang, Dan Ping Zhang, Nai Chau Sun, Rou Yun Sun, Li Wang, Yu Liang Huang, Xiao Qiang Yan
Journal: Blood (2010)
Younger Patients with CLL/SLL Are Less Frequent and Have Favorable Survival in a Canadian Population Based Study: The Manitoba Cohort.
Authors: Versha Banerji, Alain Demers, James B. Johnston, Marshall W. Pitz, Zoanne Nugent, Carmen Morales, Salah Mahmud, Donna Hewitt, Spencer B. Gibson, Matthew D. Seftel
Journal: Blood (2006)
Comparative Single Institute Analysis of Cord Blood Transplantation From Unrelated Donors with Unrelated Bone Marrow or Related Peripheral Blood Stem-Cell Transplants in Adult Patients with Acute Myeloid Leukemia / Myelodysplastic Syndrome.
Authors: Kazuhiro Masuoka, Kazuya Ishiwata, Masanori Tsuji, Shinsuke Takagi, Hisashi Yamamoto, Yuki Mori, Naofumi Matsuno, Naoyuki Uchida, Atsushi Wake, Shigeyoshi Makino, Akiko Yoneyama, Shuichi Taniguchi
Journal: Blood (2009)
Biomarker Quality Assurance (QA) Findings From the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE) Registry
Authors: Eric D. Hsi, Aaron M. Gruver, Francine M. Foss, Kenneth R. Carson, Lauren Pinter-Brown, Steven M. Horwitz, Steven T. Rosen, Barbara Pro, Massimo Federico, Christian Gisselbrecht
Journal: Blood (2012)
Deficient ADAMTS13 Activity in Ticlopidine-Associated Thrombotic Thrombocytopenic Purpura (TTP) in Populations From Japan in 2012: Validation of Findings Initially Reported in the United States in 1998 and 2000.
Authors: Charles Bennett, Masanori Matsumoto, Peter Georgantopoulos, Sony Jacob, Brianne L Dunn, Zaina Parvez Qureshi, Nicholas Bandarenko, Hau C. Kwaan, Jeffrey Winters, Ravindra Sarode, Joseph E Kiss, Constance Danielson, Thomas L. Ortel, Thomas Raife, William F Clark, Gail Rock, X. Long Zheng, Dennis Raisch, Yoshihiro Fujimura
Journal: Blood (2012)
Response to: ‘Role of ANA testing in the classification of patients with systemic lupus erythematosus’ by Pisetsky <i>et al</i>
Authors: Martin Aringer, Karen H Costenbader, Thomas Dörner, Sindhu R Johnson
Journal: Annals of the Rheumatic Diseases (2019)

In their letter,1 Drs Pisetsky, Spencer, Rovin and Lipsky very appropriately continue a highly relevant discussion on anti-nuclear antibody (ANA) testing. As Pisetsky et al point out, we had originally intended to specify ANA positivity on Hep-2 immunofluorescent testing, but grappled with the reality that increasingly other types of ANA testing are employed. Thus, the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria steering committee discussed the issues made transparent by Dr Pisetsky et al ,2 and we think that we have come to a solution that is feasible: the EULAR/ACR criteria allow for other positive …
Comparative Proteomic Profiling of Sera from Patients with Refractory Multiple Myeloma Reveals Pathways and Biomarkers Predicting Response to Bortezomib-Based Therapy
Authors: Dominik Dytfeld, Magdalena Luczak, Tomasz Szczepaniak, Anna Przybylowicz-Chalecka, Blazej Ratajczak, Joanna Czerwinska-Rybak, Adam Nowicki, Monika Joks, Andrzej Jakubowiak, Mieczyslaw Komarnicki
Journal: Blood (2016)
Establishment of Stroma-Free Cultures for Human B Lymphopoiesis: Roles of High Cell Density Condition and Mesenchymal Stem Cell-Secreted Factors.
Authors: Michiko Ichii, Kenji Oritani, Takafumi Yokota, Isao Takahashi, Takahiro Shirogane, Norimitsu Saitoh, Rie Tanigawa, Satomi Kasai, Yuzuru Kanakura
Journal: Blood (2007)
Development and initial validation of the Asthma Severity Scoring System (ASSESS)
Authors: Anne M. Fitzpatrick, Stanley J. Szefler, David T. Mauger, Brenda R. Phillips, Loren C. Denlinger, Wendy C. Moore, Ronald L. Sorkness, Sally E. Wenzel, Peter J. Gergen, Eugene R. Bleecker, Mario Castro, Serpil C. Erzurum, John V. Fahy, Benjamin M. Gaston, Elliot Israel, Bruce D. Levy, Deborah A. Meyers, W.Gerald Teague, Leonard B. Bacharier, Ngoc P. Ly, Wanda Phipatanakul, Kristie R. Ross, Joe Zein, Nizar N. Jarjour
Journal: Journal of Allergy and Clinical Immunology (2019)
Ex Vivo Expansion of Retrovirally-Transduced Primate CD34+ Cells Results in Preferential Engraftment and Persistence of Clones with MDS1/EVI1 Insertion Sites.
Authors: Theo Gomes, Stephanie Sellers, Robert E. Donahue, Rima Adler, Andre La Rochelle, Cynthia E. Dunbar
Journal: Blood (2006)
High Expression of Myocyte Enhancer Factor 2C (MEF2C) Is Associated with Adverse Risk Features and Poor Outcome in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group
Authors: George S. Laszlo, Todd A. Alonzo, Chelsea J. Gudgeon, Kimberly H. Harrington, Alex Kentsis, Robert B. Gerbing, Yi-Cheng Wang, Rhonda E. Ries, Susana C. Raimondi, Betsy A. Hirsch, Alan S. Gamis, Soheil Meshinchi, Roland B. Walter
Journal: Blood (2015)
Activation of p53 By Novel MDM2 Antagonist RG7388 Overcomes AML Inherent and Acquired Resistance to Bcl-2 Inhibitor ABT-199 (GDC-0199)
Authors: Rongqing Pan, Kensuke Kojima, Zhuanzhen Zheng, Vivian R Ruvolo, Gwen Nichols, Joel D. Leverson, Markus Dangl, Marina Konopleva, Michael Andreeff
Journal: Blood (2014)
Multi-Genomics of Relapsed B-Cell Precursor Acute Lymphoblastic Leukemia Reveals Three Distinct Genetic Clusters Characterized By Different Alterations
Authors: Michael P Schroeder, Martin Neumann, Cornelia Eckert, Lorenz Bastian, Alva Rani James, Nicola Gökbuget, Cornelia Schlee, Jutta Ortiz Tanchez, Konstandina Isaakidis, Stefan Schwartz, Thomas Burmeister, Dieter Hoelzer, Heike Pfeiffer, Michael A Rieger, Stefanie Göllner, Thomas Oellerich, Diego Yepes, Renate Kirschner-Schwabe, Monika Brüggemann, Carsten Müller-Tidow, Hubert Serve, Claudia D. Baldus
Journal: Blood (2016)
Response to Hypomethylating Agent Therapy in Acute Myeloid Leukemia Based upon Mutations in the DNA Methylation Pathway
Authors: Catherine C. Coombs, Sean Devlin, Shweta Dixit, Abhinita Mohanty, Kristina Marie Knapp, Maria Arcila, Virginia M. Klimek, Martin S Tallman, Ross L. Levine, Raajit K. Rampal, Franck Rapaport
Journal: Blood (2015)
Nonconventional Gene Expression within the NF-κb Signaling Pathway Induced By Poly(propylene)Imine Glycodendrimers in Chronic Lymphocytic Leukemia Cells
Authors: Ida Franiak-Pietryga, Kinga Ostrowska, Dietmar Appelhans, Henryk Maciejewski, Maria Bryszewska, Tadeusz Robak, Jacek Trelinski, Maciej Borowiec
Journal: Blood (2016)
Abstract 13204: Acute Effects of a Small-Molecule Direct Myosin-Attenuator (MYK-581) in a Mini-Pig Genetic Model of Non-Obstructed Hypertrophic Cardiomyopathy: In Vivo Evidence for Contractile Regulation With Improved Compliance and Functional Reserve
Authors: Carlos L del Rio, Aprajita Yadav, Neal Huang, Gail E Geist, Yukie Ueyama, Brad L Youngblood, Marc J Evanchik, Eric Green, Abhay Divekar, Ferhaan Ahmad
Journal: Circulation (2018)

Introduction: Hypertrophic cardiomyopathy (HCM) is a heritable disease characterized by hyper-contractility, impaired filling, and exertional intolerance. Direct myosin-modulation with Mavacamten c...
Imatinib Dose Can Be Safely Reduced after Complete Cytogenetic Response (CCyR) in Patients (pts) with Chronic Myeloid Leukemia (CML) in Early Chronic Phase (CP) Treated with High-Dose Imatinib.
Authors: Nitin Jain, Hagop M. Kantarjian, Carmen Fava, Deborah Thomas, Jan A. Burger, Gautam Borthakur, Odeal Pate, Jorge Cortes
Journal: Blood (2007)
A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis
Authors: James Chih-Hsin Yang, Ying Cheng, Haruyasu Murakami, Pan-Chyr Yang, Jianxing He, Kazuhiko Nakagawa, Jin Hyoung Kang, Joo-Hang Kim, Rebecca R. Hozak, Tuan Stevon Nguyen, Wan Li Zhang, Sotaro Enatsu, Tarun Puri, Mauro Orlando
Journal: Journal of Thoracic Oncology (2019)

IntroductionClinical studies have shown that a combination of a tyrosine kinase inhibitor (TKI) and pemetrexed overcame acquired resistance to epidermal growth factor receptor (EGFR) TKI in NSCLC. Previously, pemetrexed+gefintib (P+G) had improved progression-free survival (PFS) compared with gefitinib. We present OS, updated PFS, biomarker analysis, and safety of P+G versus gefitinib.MethodsThis was a phase 2, multicenter, randomized study conducted in East Asian patients with advanced nonsquamous NSCLC with EGFR mutations. Patients were randomized (2:1) to receive P+G (500 mg/m2 intravenously 3-weekly + 250 mg/day orally) or gefitinib.ResultsIn total, 191 patients (P+G, n=126; gefitinib, n=65) comprised the intent-to-treat and safety populations. Median OS was 43.4 months in P+G versus 36.8 months in gefitinib arm; adjusted HR 0.77 (95% CI, 0.5-1.2); one-sided P=0.105. Median PFS was significantly longer in the P+G (16.2 months) versus gefitinib arm (11.1 months); adjusted HR 0.67 (95% CI, 0.5-0.9); one-sided P=0.009. In the P+G and gefitinib arms, median PFS was 22.6 and 11.0 months, respectively, in patients with low thymidylate synthase (TS) expression, and 12.6 and 9.9 months, respectively, in patients with high TS expression. Common second-line post-discontinuation systemic therapies were EGFR-TKIs and chemotherapy. Most patients experienced at least one adverse event.ConclusionsAddition of pemetrexed to EGFR TKI gefitinib resulted in significantly improved PFS and numerically longer OS compared with gefitinib in treatment-naïve patients with EGFR-mutated advanced nonsquamous NSCLC. Low TS expression appeared to be a good predictor for treatment outcomes.
The Jak2 V617F Oncogene Associated with Polycythemia Vera Requires a Functional FERM Domain for Transformation and for Expression of the Myc and Pim Proto-Oncogenes.
Authors: Martin Sattler, Brian J. Crowley, Jeffrey R. Gonneville, Jeremy Ho, Heidi H. Hudon, Klaus Podar, Yohan Royer, Stefan N. Constantinescu, James D. Griffin
Journal: Blood (2006)